Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06680544
PHASE2

Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections

Sponsor: Sheikh Zayed Medical College

View on ClinicalTrials.gov

Summary

Treatment of dermatophyte infection in our country (Pakistan) is becoming difficult due to the developing resistance to traditional antifungal agents. Assessing the effectiveness ,feasibility and standard dosage of a newer antifungal drug like voriconazole is the need of the hour in resistant cases of dermatophyte infection.

Official title: Comparing the Efficacy of Oral 200 Milligram Voriconazole Once a Day Vs. Twice a Day in the Treatment of Resisitant Dermatophyte Infections (Tinea Corporis and Tinea Cruris)

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2024-11-15

Completion Date

2025-03-15

Last Updated

2024-11-08

Healthy Volunteers

No

Interventions

DRUG

Voriconazole high dose

Oral voriconazole 200mg once a day for a maximum of 28 days

DRUG

Voriconazole low dose

Oral voriconazole 200mg twice a day for a maximum of 28 days

Locations (1)

Sheikh zayed Medical College and Hospital

Rahim Yar Khan, Punjab Province, Pakistan